Soluble PD-L1 as an early marker of progressive disease on nivolumab

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Background Soluble PD-L1 (sPD-L1) has been associated with worse prognosis in numerous solid tumors. We determined sPD-L1 levels before and during nivolumab treatment in two prospective clinical trials of metastatic clear cell renal cell carcinoma (RCC) and melanoma patients, and investigated its re...

Full description

Bibliographic Details
Main Authors: Choueiri, T.K (Author), Freeman, G.J (Author), Mahoney, K.M (Author), Mcdermott, D.F (Author), Ross-Macdonald, P. (Author), Song, L. (Author), Stephen Hodi, F. (Author), Veras, E. (Author), Wind-Rotolo, M. (Author), Yuan, L. (Author)
Format: Article
Language:English
Published: BMJ Publishing Group 2022
Subjects:
Antineoplastic Agents, Immunological
Article
B7-H1 Antigen
biomarkers
Biomarkers, Tumor
cancer growth
CD274 protein, human
clear cell renal cell carcinoma
cohort analysis
disease exacerbation
Disease Progression
female
Female
gene expression
Gene Expression
gene expression profiling
gene mutation
gene set enrichment analysis
genetics
human
human tissue
Humans
immunoassay
immunohistochemistry
immunological antineoplastic agent
immunotherapy
Immunotherapy
kidney metastasis
kidney neoplasms
male
Male
melanoma
metabolism
nivolumab
Nivolumab
overall response rate
overall survival
phase 1 clinical trial (topic)
procedures
prognosis
Prognosis
programmed death 1 ligand 1
progression free survival
Prospective Studies
prospective study
transcriptomics
treatment response
tumor
tumor marker
tumor volume
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items